TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: Therapeutic utility in the era of IL-17 and IL-23 inhibitors
JJ Hong, EK Hadeler, ML Mosca… - Journal of psoriasis …, 2022 - journals.sagepub.com
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors
JJ Hong, EK Hadeler, ML Mosca… - … of psoriasis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.
JJ Hong, EK Hadeler, ML Mosca… - Journal of Psoriasis …, 2022 - europepmc.org
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.
J Hong, E Hadeler, M Mosca… - Journal of Psoriasis …, 2022 - escholarship.org
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
[HTML][HTML] TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors
JJ Hong, EK Hadeler, ML Mosca… - Journal of psoriasis …, 2022 - ncbi.nlm.nih.gov
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.
JJ Hong, EK Hadeler, ML Mosca… - Journal of Psoriasis …, 2022 - europepmc.org
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …